Trials / Completed
CompletedNCT01645969
A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265
A Follow-up Study to Evaluate the One-year Post Treatment Effects of Peginterferon Alfa-2a (PEGASYS) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study ML 22265
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, prospective, observational study will evaluate the one-year outcomes in HBeAg positive chronic hepatitis B patients who had received Pegasys (peginterferon alfa-2a) in Arm A of study ML22265. Data will be collected from each patient for up to one year post-therapy.
Conditions
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-07-20
- Last updated
- 2016-11-02
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01645969. Inclusion in this directory is not an endorsement.